



US009259428B2

(12) **United States Patent**
Lulla et al.

(10) **Patent No.:** **US 9,259,428 B2**
(45) **Date of Patent:** ***Feb. 16, 2016**

(54) **COMBINATION OF AZELASTINE AND FLUTICASONE FOR NASAL ADMINISTRATION**
(71) Applicant: **Cipla Limited, Mumbai (IN)**
(72) Inventors: **Amar Lulla, Mumbai (IN); Geena Malhotra, Mumbai (IN)**
(73) Assignee: **Cipla Limited, Mumbai (IN)**
(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
This patent is subject to a terminal disclaimer.

3,557,162 A 1/1971 Lens et al.
3,639,434 A 2/1972 Oxley et al.
3,755,302 A 8/1973 Ercoli et al.
3,813,384 A 5/1974 Vogelsang et al.
3,828,080 A 8/1974 Phillipps et al.
3,856,828 A 12/1974 Phillipps et al.
3,891,631 A 6/1975 Phillipps et al.
3,981,894 A 9/1976 Phillipps et al.
3,989,686 A 11/1976 Phillipps et al.
4,093,721 A 6/1978 Phillipps et al.
4,113,680 A 9/1978 Kamano et al.
4,187,301 A 2/1980 Edwards
4,188,385 A 2/1980 Edwards
4,198,403 A 4/1980 Alvarez
4,221,787 A 9/1980 Bodor et al.
4,261,984 A 4/1981 Alvarez
4,263,289 A 4/1981 Edwards
4,267,173 A 5/1981 Draper
4,285,937 A 8/1981 Kalvoda
4,310,466 A 1/1982 Edwards
4,335,121 A 6/1982 Phillipps et al.
4,377,575 A 3/1983 Stache et al.
4,472,393 A 9/1984 Shapiro
4,607,028 A 8/1986 Schmidlin
4,710,495 A 12/1987 Bodor
4,861,765 A 8/1989 Mitsukuchi et al.
4,992,474 A 2/1991 Skidmore et al.
4,994,439 A 2/1991 Longenecker et al.
4,996,335 A 2/1991 Bodor
5,063,222 A 11/1991 Komoto et al.
5,081,113 A 1/1992 Claussner et al.
5,086,050 A 2/1992 Hetteche et al.
5,164,194 A 11/1992 Hetteche

(21) Appl. No.: **14/661,720**

(22) Filed: **Mar. 18, 2015**

(65) **Prior Publication Data**
US 2015/0190405 A1 Jul. 9, 2015

Related U.S. Application Data

(60) Continuation of application No. 14/539,646, filed on Nov. 12, 2014, which is a continuation of application No. 13/644,127, filed on Oct. 3, 2012, now Pat. No. 8,937,057, which is a continuation of application No. 12/508,388, filed on Jul. 23, 2009, now Pat. No. 8,318,709, which is a division of application No. 10/518,016, filed as application No. PCT/GB03/02557 on Jun. 13, 2003, now Pat. No. 8,168,620.

(51) **Int. Cl.**
A61K 31/56 (2006.01)
A61K 9/00 (2006.01)
A61K 31/55 (2006.01)
A61K 31/573 (2006.01)
A61K 31/58 (2006.01)
A61K 47/10 (2006.01)
A61K 47/18 (2006.01)
A61K 47/26 (2006.01)
A61K 47/38 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 31/56** (2013.01); **A61K 9/0043** (2013.01); **A61K 31/55** (2013.01); **A61K 31/573** (2013.01); **A61K 31/58** (2013.01); **A61K 47/10** (2013.01); **A61K 47/183** (2013.01); **A61K 47/186** (2013.01); **A61K 47/26** (2013.01); **A61K 47/38** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS

2,837,464 A 6/1958 Nobile
3,067,197 A 12/1962 Agnello et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AU 2003244799 B2 12/2003
BE 889563 A1 11/1981
DE 1059906 B 6/1959
DE 2164058 A1 7/1972
DE 3836579 A1 5/1989
DE 19947234 A1 4/2001
DE 10152369 A1 5/2002
EP 0004773 A2 10/1979
EP 0057401 A1 8/1982
EP 0179583 A1 4/1986

(Continued)

OTHER PUBLICATIONS

European Search Report dated May 12, 2009, EP 09075101, 2 pages.
(Continued)

Primary Examiner — Robert A Wax
Assistant Examiner — Thor Nielsen
(74) *Attorney, Agent, or Firm* — Conley Rose, P.C.; Rodney B. Carroll

(57) **ABSTRACT**

A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.

(56)

References Cited

U.S. PATENT DOCUMENTS

5,202,316	A	4/1993	Claussner et al.	2004/0242638	A1	12/2004	Yanni et al.
5,232,919	A	8/1993	Scheffler et al.	2005/0163724	A1	7/2005	Miyadai et al.
5,271,946	A	12/1993	Hettche	2005/0192261	A1	9/2005	Jost-Price et al.
5,362,721	A	11/1994	Stache et al.	2006/0002861	A1	1/2006	Biggadike
5,420,120	A	5/1995	Boltralik	2006/0228306	A1	10/2006	Lane
5,608,093	A	3/1997	Stache et al.	2007/0020330	A1	1/2007	Dang et al.
5,658,549	A	8/1997	Akehurst et al.	2009/0124585	A1	5/2009	Cross et al.
5,658,919	A	8/1997	Ratnaraj et al.	2009/0156567	A1	6/2009	Biggadike
5,707,984	A	1/1998	Tjoeng et al.	2009/0286762	A1	11/2009	Myles et al.
5,830,490	A	11/1998	Weinstein et al.	2010/0152147	A1	6/2010	Fuge et al.
5,837,699	A	11/1998	Sequeira et al.	2010/0311706	A1	12/2010	Biggadike et al.
5,849,265	A	12/1998	Li-Bovet et al.	2012/0065177	A1	3/2012	Myles et al.
5,889,015	A	3/1999	Sequeira et al.	2015/0072010	A1	3/2015	Lulla et al.
5,914,122	A	6/1999	Otterbeck et al.				
5,972,920	A	10/1999	Seidel				
5,981,517	A	11/1999	Bodor				
6,017,963	A	1/2000	Alfonso et al.				
6,057,307	A	5/2000	Sequeira et al.				
6,127,353	A	10/2000	Yuen et al.				
6,136,294	A	10/2000	Adjei et al.				
6,197,761	B1	3/2001	Biggadike et al.				
6,241,969	B1	6/2001	Saidi et al.				
6,261,539	B1	7/2001	Adjei et al.				
6,294,153	B1	9/2001	Modi				
6,319,513	B1	11/2001	Dobrozsi				
6,330,938	B1	12/2001	Hérvé et al.				
6,391,340	B1	5/2002	Malmqvist-Granlund et al.				
6,395,300	B1	5/2002	Straub et al.				
6,416,743	B1	7/2002	Fassberg et al.				
6,537,983	B1	3/2003	Biggadike et al.				
6,583,180	B2	6/2003	Link et al.				
6,750,210	B2	6/2004	Biggadike				
6,759,398	B2	7/2004	Biggadike				
6,777,399	B2	8/2004	Biggadike et al.				
6,777,400	B2	8/2004	Biggadike et al.				
6,787,532	B2	9/2004	Biggadike et al.				
6,835,724	B2	12/2004	Stache et al.				
6,858,593	B2	2/2005	Biggadike et al.				
6,858,596	B2	2/2005	Biggadike et al.				
6,878,698	B2	4/2005	Biggadike et al.				
6,881,423	B2	4/2005	Dohi et al.				
6,921,757	B2	7/2005	Cuenoud et al.				
7,101,866	B2	9/2006	Biggadike et al.				
7,125,985	B2	10/2006	Biggadike et al.				
7,132,532	B2	11/2006	Biggadike et al.				
7,144,845	B2	12/2006	Biggadike et al.				
7,214,672	B2	5/2007	Komoto et al.				
7,244,742	B2	7/2007	Pieper et al.				
7,288,536	B2	10/2007	Biggadike et al.				
7,291,608	B2	11/2007	Biggadike et al.				
7,291,609	B2	11/2007	Biggadike et al.				
7,405,206	B2	7/2008	Biggadike et al.				
7,498,321	B2	3/2009	Biggadike et al.				
7,524,970	B2	4/2009	John				
7,531,528	B2	5/2009	Biggadike et al.				
7,541,350	B2	6/2009	Biggadike et al.				
7,579,335	B2	8/2009	Biggadike et al.				
7,592,329	B2	9/2009	Biggadike et al.				
7,629,335	B2	12/2009	Biggadike et al.				
7,638,508	B2	12/2009	Biggadike et al.				
7,776,315	B2	8/2010	Pairet et al.				
8,071,073	B2	12/2011	Dang et al.				
8,163,723	B2	4/2012	Lulla et al.				
8,168,620	B2	5/2012	Lulla et al.				
8,304,405	B2	11/2012	Lulla et al.				
8,318,709	B2	11/2012	Lulla et al.				
8,933,060	B2	1/2015	Lulla et al.				
8,937,057	B2	1/2015	Lulla et al.				
2002/0061281	A1	5/2002	Osbakken et al.				
2002/0076382	A1	6/2002	Kaplan et al.				
2002/0081266	A1	6/2002	Woolfe et al.				
2003/0018019	A1	1/2003	Meade et al.				
2004/0136918	A1	7/2004	Garrett et al.				
				EP	0393658	B1	10/1990
				EP	0416951	A1	3/1991
				EP	0780127	A1	6/1997
				EP	1519731	B1	4/2009
				EP	2072051	A1	6/2009
				EP	2075000	A1	7/2009
				GB	1191965		5/1970
				GB	1296458		11/1972
				GB	1384372		2/1975
				GB	1438940		6/1976
				GB	1517278		7/1978
				GB	2079755	A	1/1982
				GB	2088877	A	6/1982
				GB	2140800	A	12/1984
				GB	2389530	A	12/2003
				IL	109656	A	2/1998
				JP	4208267	A	7/1992
				JP	8291072	A	11/1996
				JP	8291073	A	11/1996
				JP	200253485	A	2/2002
				WO	8504589	A1	10/1985
				WO	8903390	A1	4/1989
				WO	9015816	A1	12/1990
				WO	9104252	A1	4/1991
				WO	9214472	A1	9/1992
				WO	9531964	A1	11/1995
				WO	9619199	A1	6/1996
				WO	9632151	A1	10/1996
				WO	9701337	A1	1/1997
				WO	9705136	A1	2/1997
				WO	9715298	A1	5/1997
				WO	9721721	A1	6/1997
				WO	9721724	A1	6/1997
				WO	9724365	A1	7/1997
				WO	9731626	A1	9/1997
				WO	9740836	A1	11/1997
				WO	9746243	A1	12/1997
				WO	9817676	A1	4/1998
				WO	9834596	A2	8/1998
				WO	9848839	A1	11/1998
				WO	9901467	A2	1/1999
				WO	9925359	A1	5/1999
				WO	9932089	A1	7/1999
				WO	0016814	A1	3/2000
				WO	0033892	A1	6/2000
				WO	0038811	A1	7/2000
				WO	0048587	A1	8/2000
				WO	0049993	A2	8/2000
				WO	0066522	A1	11/2000
				WO	0104118	A2	1/2001
				WO	01020331	A1	3/2001
				WO	0154481	A2	8/2001
				WO	0154664	A1	8/2001
				WO	0157025	A1	8/2001
				WO	0162722	A2	8/2001
				WO	0178736	A1	10/2001
				WO	0178739	A1	10/2001
				WO	0178741	A1	10/2001
				WO	0178745	A1	10/2001
				WO	0200199	A1	1/2002
				WO	0200679	A2	1/2002

FOREIGN PATENT DOCUMENTS

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	0208243	A1	1/2002
WO	0211711	A2	2/2002
WO	0212265	A1	2/2002
WO	0212266	A1	2/2002
WO	0213868	A1	2/2002
WO	0226723	A1	4/2002
WO	0236106	A2	5/2002
WO	02051422	A1	7/2002
WO	02053186	A2	7/2002
WO	02066422	A1	8/2002
WO	02070490	A1	9/2002
WO	02076933	A1	10/2002
WO	02085296	A2	10/2002
WO	02088167	A1	11/2002
WO	02100879	A1	12/2002
WO	03000241	A2	1/2003
WO	03013427	A2	2/2003
WO	03033000	A1	4/2003
WO	03035668	A2	5/2003
WO	03040691	A2	5/2003
WO	03042229	A1	5/2003
WO	03042230	A1	5/2003
WO	03048181	A1	6/2003
WO	03062259	A2	7/2003
WO	03064445	A1	8/2003
WO	03066033	A1	8/2003
WO	03066036	A1	8/2003
WO	03066656	A1	8/2003
WO	03072592	A1	9/2003
WO	03086399	A1	10/2003
WO	03105856	A1	12/2003
WO	2004013156	A1	2/2004
WO	2004019955	A1	3/2004
WO	2005005451	A1	1/2005
WO	2005005452	A1	1/2005
WO	2006058022	A1	6/2006
WO	2007061454	A1	5/2007
WO	2008012338	A2	1/2008
WO	2008012338	A3	1/2008
ZA	872389		4/1987

OTHER PUBLICATIONS

Settipane, Guy, et al., "Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study," *Clinical Therapeutics*, 1995, vol. 17, No. 2, pp. 252-263.

Shapiro, Elliot L., et al., "17 heteroaroyl esters of corticosteroids 2. 11 β -hydroxy series," *Journal of Medicinal Chemistry*, vol. 30, No. 9, 1987, pp. 1581-1588, American Chemical Society.

Shapiro, Elliot, et al., "17-esters and 17,21-diester of 9- α , 11- β -dichlorocorticoids. Synthesis and anti-inflammatory activity," *Steroids*, vol. 9, No. 2, pp. 143-156, Feb. 1967.

Shapiro, Elliot L., et al., "Synthesis and structure-activity studies of corticosteroid 17-heterocyclic aromatic esters. 1. 9 α ,11 β -dichloro series," *Journal of Medicinal Chemistry*, vol. 30, No. 6, pp. 1068-1073, 1987, American Chemical Society.

Shenfield, Gillian M., "Fixed drug combinations: which ones can be recommended?" *Current Therapeutics*, Dec. 1986, pp. 15, 16, 22-24, 27-29.

Simpson, Richard J., "Budesonide and terfenadine, separately and in combination, in the treatment of hay fever," *Annals of Allergy*, Dec. 1994, vol. 73, pp. 497-502 plus cover and publication pages, American College of Allergy and Immunology.

Smith, Carolyn L., et al., "In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids," *Arzneim-Forsch./Drug Res.*, 1998, vol. 48 (II), No. 9, pp. 956-959.

Smith, N., et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary

Souness, et al., "Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors," *Immunopharmacology*, 2000, vol. 47, pp. 127-162, Elsevier Science B.V.

Spector, Sheldon, "Ideal pharmacotherapy for allergic rhinitis," *J Allergy Clin Immunol*, 1999, vol. 103, No. 3, Part 2, pp. S386-S387, Mosby, Inc.

Study No. 03DMW062—"Pharmacokinetics of GW685698X and CCI18781 (fluticasone propionate) when co-administered by the intratracheal or intravenous route to the anaesthetised white pig," 2004, 21 pages.

Study No. B30947—"The Pharmacokinetics of GW685698X and CCI18781 following intratracheal co-administration to the anaesthetised white pig," 2003, 20 pages.

Szefer, Stanley J., et al., Chapter 21, "Glucocorticoids in severe asthma: mechanisms of action and route of administration," *Difficult Asthma*, pp. 371-375, Martin Dunitz Ltd, 1999.

Tanaka, Akira, et al., "Synthesis of 4H-furo[3,2-b]indole derivatives. III (1). Preparation of 4H-furo[3,2-b]indole-2-carboxylic acid derivatives," vol. 16, pp. 785-788, Jun. 1979, HeteroCorporation.

The United States Pharmacopoeia, 23rd Edition, U.S. Pharmacopoeia Convention, Inc., 1995, pp. 1843-1844, "Physical Tests / X-ray Diffraction (941)."

Ueno, Hiroaki, et al., "Synthesis and evaluation of antiinflammatory activities of a series of corticosteroid 17 α -esters containing a functional group," *Journal of Medicinal Chemistry*, vol. 34, No. 8, 1991, pp. 2468-2473.

Van As, Andre, et al., "Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone dipropionate," *J. Allergy Clin. Immunol.*, 1993, vol. 91, No. 6, pp. 1146-1154.

Van Bavel, J. H., et al., "Ocular efficacy and clinician overall evaluation of intranasal fluticasone propionate (FP) versus loratadine (LOR) in seasonal allergic rhinitis (SAR)," *Annals of Allergy, Asthma, & Immunology*, 1997, vol. 78, p. 128, Abstract P101.

Van Der Molen, T., et al., "Effects of the long acting β agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids," *Thorax*, vol. 52, 1996, pp. 535-539 plus information page.

Vanrell, Herrero, "Preservatives in ophthalmic formulations: an overview," *Arch Soc Esp Oftalmol*, 2007, vol. 82, pp. 531-532.

Veramyst™ (fluticasone furoate) Nasal Spray, GlaxoSmithKline, Apr. 2007, Summary Sheet, pp. 1-20.

Wang, De-Yun, "Treatment of Allergic Rhinitis: H1-Antihistamines and Intranasal Steroids," *Current Drug Targets—Inflammation & Allergy*, 2002, vol. 1, pp. 215-220, Bentham Science Publishers Ltd.

Westlund, Ronald, et al., "Fluticasone propionate aqueous nasal spray 200 mg once daily provides relief of ocular symptoms associated with seasonal allergic rhinitis," 57th Annual Meeting of the American Academy of Allergy, Asthma and Immunology, New Orleans, Louisiana, Mar. 16-21, 2001, Abstract No. 522, 1 page.

World Review 2001: The Pharmaceutical Market, vol. 1 International, IMS Health, 2001, cover, preface, and copyright pages plus pp. 4-42 and 5-1 through 5-11, IMS A.G.

Foreign communication from a related counterpart application—Pre-Grant Opposition, 1696/MUMNP/2009, Jun. 27, 2012, 124 pages. PCT/GB01/03495, International Search Report, Oct. 17, 2001, 2 pages.

PCT/GB01/03495, International Preliminary Examination Report, Aug. 30, 2002, 11 pages.

PCT/EP2007/057695, International Search Report and Written Opinion, Oct. 28, 2008, 16 pages.

PCT/EP2007/057695, International Preliminary Report on Patentability, Feb. 3, 2009, 8 pages.

Document submitted in the Opposition proceedings regarding European Patent No. 1519731, D35, Units and Sales for Corticosteroids in 2009 and 2010, Oct. 5, 2011, 3 pages.

Document submitted in the Opposition proceedings regarding European Patent No. 1519731, D36, Stability tests, Oct. 5, 2011, 4 pages.

Office Action dated Jul. 11, 2011—20632 IL, 3 pages.

(56)

References Cited

OTHER PUBLICATIONS

Office Action dated Nov. 30, 2010 (16 pages), U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.

European Search Report dated May 12, 2009, EP 09075100, 3 pages.
Sandham, David A., et al., "Synthesis and biological properties of novel glucocorticoid androstene C-17 furoate esters," *Bioorganic & Medicinal Chemistry*, 2004, vol. 12, pp. 5213-5224, Elsevier Ltd.

Scadding, Glenis K., et al., "Clinical and physiological effects of fluticasone propionate aqueous nasal spray in the treatment of perennial rhinitis," *Rhinology*, 1991, Suppl. 11, pp. 37-43.

Schmidt, Bernhard M. W., et al., "The New Topical Steroid Ciclesonide is Effective in the Treatment of Allergic Rhinitis," *Journal of Clinical Pharmacology*, 1999, vol. 39, pp. 1062-1069, American College of Clinical Pharmacology.

Ong, John T. H., et al., "Intrinsic potencies of novel thiol ester corticosteroids RS-85095 and RS-21314 as compared with clobetasol 17-propionate and flucocinonide," *Arch Dermatol*, vol. 125, Dec. 1989, pp. 1662-1665.

Ong, John T. H., et al., "Micellar solubilization of timobesone acetate in aqueous and aqueous propylene glycol solutions of nonionic surfactants," *Pharmaceutical Research*, vol. 5, No. 11, 1988, pp. 704-708, Plenum Publishing Corporation.

Omrust, Susan B., et al., "Mometasone furoate: a review of its intranasal use in allergic rhinitis," *Drugs*, vol. 56, No. 4, Oct. 1998, pp. 725-745, Adis International Limited.

Opponent's submission dated Oct. 6, 2011 to European Patent No. 1519731, 2 pages.

Opponent's submission dated Sep. 23, 2011 regarding additional documents on European Patent No. 1519731, 2 pages.

Opponent's submission dated Sep. 23, 2011 regarding list of attendees at oral proceedings on European Patent No. 1519731, 1 page.

Patentee's response of Sep. 6, 2010 of European Patent No. 1519731, 49 pages.

Opposition to EP 1519731, Aug. 8, 2011, 19 pages.

Patentee's submission dated Sep. 19, 2011 on European Patent No. 1519731, 1 page.

Patentee's submission dated Sep. 29, 2011 regarding list of attendees at oral proceedings on EP Patent No. 1519731, 1 page.

Phillipps, Gordon H., et al., "Synthesis and structure—activity relationships in a series of anti-inflammatory corticosteroid analogues, halomethyl androstane—17 β -carbothioates and—17 β -carbosenoates," *Journal of Medicinal Chemistry*, 1994, vol. 37, No. 22, pp. 3717-3729, American Chemical Society.

Popper, Thomas L., et al., "Structure-activity relationships of a series of novel topical corticosteroids," *J. steroid Biochem.*, 1987, vol. 27, No. 4-6, pp. 837-843, Pergamon Journals Ltd.

Portmann, D. et al., "Acceptability of local treatment of allergic rhinitis with a combination of a corticoid (beclomethasone) and an antihistaminic (azelastine), XP-002252974, 2000, 1 page, Medline. Pre-Grant Opposition, Indian Patent Application 2092/KOLNP/2007 dated Jun. 8, 2007, 183 pages.

Prescribing Information for ASTEPRO®, Nov. 2010, 20 pages, Meda Pharmaceuticals Inc.

Prescribing Information for RHINOCORT AQUA®, Dec. 2010, 32 pages, AstraZeneca LP.

Preservative, definition of. Composite definition of preservative in the Medical dictionary, from internet site <http://medical-dictionary.thefreedictionary.com/preservative>, Nov. 4, 2009, 3 pages.

Product Information Rhinocort Aqua® (budesonide) Nasal Spray 32 mcg, Jan. 2005, 2 pages.

Product Information, Nasonex® (mometasone furoate monohydrate) Nasal Spray 50 mcg, Aug. 2001, 22 pages, Schering Corporation.

Product Specification Bulletin, Avicel® CL-611, Bulletin AVC611-SPEC-02/09.RS, Feb. 2009, 2 pages, FMC Corporation.

Rapid Response Report: Summary with Critical Appraisal, "Fluticasone Furoate versus Fluticasone Propionate for Seasonal Allergic Rhinitis: A Review of the Clinical and Cost Effectiveness," Jun. 13, 2011, 8 pages, Canadian Agency for Drugs and Technologies in Health.

Ratner, Paul H., et al., "A Comparison of the Efficacy of Fluticasone Propionate Aqueous Nasal Spray and Loratadine, Alone and in Combination, for the Treatment of Seasonal Allergic Rhinitis," *The Journal of Family Practice*, Aug. 1998, vol. 47, No. 2, pp. 118-125 plus cover and publishing pages, Appleton & Lange.

Ratner, Paul H., et al., "Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis," *Annals of Allergy, Asthma & Immunology*, Jan. 2008, vol. 100, pp. 74-81.

Reddy, Indra K., "Ocular Therapeutics and Drug Delivery: A Multi-Disciplinary Approach," 1996, pp. 382-385 plus cover and publishing pages, Technomic Publishing Company, Inc.

Result of oral proceedings dated Oct. 12, 2011 of EP Patent No. 1519731, 5 pages.

Safety Data Sheet No. 110536, Jun. 23, 2008, Version 13, Beconase Hayfever Allergy Spray, 5 pages, GlaxoSmithKline.

Safety Data Sheet No. 110556, Jul. 4, 2008, Version 14, Flonase Nasal Spray, 5 pages, GlaxoSmithKline.

Sakagami, Masahiro, et al., "Mucoadhesive BDP microspheres for powder inhalation—their unique pharmacokinetic-pharmacodynamic profiles," *Respiratory Drug Delivery*, vol. VI, pp. 193-199, 1998.

Salib, Rami Jean, et al., "Safety and Tolerability Profiles of Intranasal Antihistamines and Intranasal Corticosteroids in the Treatment of Allergic Rhinitis," *Drug Safety*, 2003, vol. 26, No. 12, pp. 863-893 plus cover and publishing pages, ADIS Data Information BV.

Baldwin C. M., et al., abstract, "Mometasone furoate: a review of its intranasal use in allergic rhinitis," 2008, 1 page, [Drugs, pp. 1723-1739, vol. 68, No. 12].

Bielory, L., et al., "Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis," *Allergy*, 2011, pp. 686-693, vol. 66, John Wiley & Sons A/S.

ClinicalTrials.gov, "A study of the effectiveness and safety of mometasone furoate nasal spray (MFNS, SCH032088) for the treatment of nasal polyps (P05604)," <http://clinicaltrials.gov/ct2/show/NCT01386125>, Mar. 14, 2013, 3 pages, Merck.

ClinicalTrials.gov, "Mometasone furoate nasal spray for treatment of nasal polyposis after surgery (study P03218)," <http://clinicaltrials.gov/ct2/show/NCT00731185>, Aug. 7, 2008, 3 pages, Schering-Plough.

Makihara, Seiichiro, et al., "Early interventional treatment with intranasal mometasone furoate in Japanese cedar/cypress pollinosis: a randomized placebo-controlled trial," *Allergology International*, 2012, pp. 295-304, vol. 61, No. 2, Japanese Society of Allergology.

Small, Catherine Butkus, et al., "Efficacy and safety of mometasone furoate nasal spray in nasal polyposis," *J Allergy Clin Immunol*, Dec. 2005, pp. 1275-1281, American Academy of Allergy, Asthma and Immunology.

Stjärne, Pär, et al., "Use of mometasone furoate to prevent polyp relapse after endoscopic sinus surgery," *Arch Otolaryngol Head Neck Surg*, Mar. 2009, pp. 296-302, vol. 135, No. 3, American Medical Association.

Vuralcan, Erkan, et al., "Comparison of montelukast and mometasone furoate in the prevention of recurrent nasal polyps," 2012, pp. 5-10, vol. 6, No. 1, Therapeutic Advances in Respiratory Disease.

Office communication dated Jul. 6, 2011 (3 pages), U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.

Office Action dated Jul. 15, 2013 (48 pages), U.S. Appl. No. 13/204,978, filed Aug. 8, 2011.

ClinicalTrials.gov, "Efficacy and safety of mometasone furoate plus azelastine HCl combination versus mometasone furoate alone or azelastine alone in patients with perennial allergic rhinitis (NCT01470053)," <http://clinicaltrials.gov/ct2/show/NCT01470053>, Aug. 26, 2013, 3 pages, Hanlim Pharm. Co., Ltd.

1 page summary of "Evaluation of fluticasone propionate aqueous nasal spray taken alone and in combination with cetirizine in the

(56)

References Cited

OTHER PUBLICATIONS

- Finn, Jr., A. F., et al., 1 page abstract of "Efficacy of three different dosing regimens of fluticasone propionate (FP) aqueous nasal spray in the treatment of perennial nonallergic rhinitis (PNAR)," *J Allergy Clin Immunol*, Jan. 1997, Ref. No. 1787.
- Graft, David, et al., "A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray," *J Allergy Clin Immunol*, Oct. 1996, pp. 724-731, vol. 98, No. 4, Mosby-Year Book, Inc.
- Marazzi, P., et al., 1 page abstract of "Prophylactic use of once-daily mometasone furoate (Nasonex) aqueous nasal spray in patients with seasonal allergic rhinitis," *J Allergy Clin Immunol*, Jan. 1997, Ref. No. 1789.
- Nakabayashi, S., et al., 1 page abstract of "The effect of initial treatment by FP aqueous nasal spray in patients with Japanese cedar pollinosis," Sep. 1996, vol. 99, No. 9, pp. 1162-1171.
- Simon, Michael W., 1 page abstract of "The efficacy of azelastine in the prophylaxis of acute upper respiratory tract infections," *Allergy & Immunology*, Dec. 2003, vol. 16, No. 4, pp. 275-282.
- Trangsrud, Amanda J., et al., "Intranasal corticosteroids for allergic rhinitis," *Pharmacotherapy*, 2002, vol. 22, No. 11, 14 pages, Pharmacotherapy Publications.
- Yamagishi, Masuo, et al., 1 page abstract of "Azelastine in the treatment and prevention of seasonal grass pollinosis," *Practica Oto-Rhino-Laryngologica*, 1991, pp. 1345-1353, vol. 84, No. 9.
- "Allergic Rhinitis and its Impact on Asthma (ARIA) 2008," *European Journal of Allergy and Clinical Immunology*, Apr. 2008, 162 pages, vol. 63, No. 86, Wiley-Blackwell, Copenhagen, Denmark.
- Aria Workshop Report entitled "Allergic Rhinitis and its Impact on Asthma," *The Journal of Allergy and Clinical Immunology*, Nov. 2001, 205 pages, vol. 108, No. 5, Mosby.
- Astelín Product Information, Jul. 2011, 8 pages, Meda Pharmaceuticals Inc.
- Berger, William E., et al., "Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis," *Annals of Allergy, Asthma & Immunology*, Jun. 1999, pp. 535-541, vol. 82.
- Communication of Notice of Opposition in a foreign counterpart application, European Patent No. 2072051, Nov. 6, 2014, 19 pages.
- Comparative Composition data of Azelastine with steroids table filed by patentee, 20632A-EP, Nov. 2, 2010, 2 pages.
- European Sales Data Table, 2001-2005, 3 pages.
- Nasacort® AQ (triamcinolone acetonide) Product Leaflet, Nov. 2010, 5 pages, sanofi-aventis U.S. LLC.
- Opponent/Appellant's Statement of Grounds of Appeal against the Interlocutory Decision in Opposition Proceedings in a foreign counterpart application, European Patent No. 1 519 731 B1, May 28, 2012, 62 pages.
- Pawankar, Ruby, "Allergic Rhinitis and Its Impact on Asthma: An Evidence-Based Treatment Strategy for Allergic Rhinitis," *Asian Pacific Journal of Allergy and Immunology*, Mar. 2002, pp. 43-52 plus 1 page publishing information, vol. 20, No. 1, Allergy, Asthma and Immunology Society of Thailand.
- Reichmuth, Daniel, et al., "Present and Potential Therapy for Allergic Rhinitis," *BioDrugs*, Dec. 2000, pp. 371-387, vol. 14, No. 6, Adis International Limited.
- Reply of Patentee to Grounds of Appeal in a foreign counterpart application, European Patent No. 1 519 731 B1, Feb. 14, 2013, 46 pages.
- Rote Liste® catalog of drugs marketed in Germany in the year 2002, entries 07 079 and 07 080 (Allergodil, nasal spray (solution)), and 72 025 (Nasonex, nasal spray (suspension)), 3 pages, Rote Liste® Service GmbH, Frankfurt.
- Scadding, G. K., "Clinical assessment of antihistamines in rhinitis," Stricker, W. E., et al., "Fluticasone Propionate Aqueous Nasal Spray (FP) and Loratadine (LOR), Alone and in Combination, in the Treatment of Fall Seasonal Allergic Rhinitis (SAR)," Ref. No. P62, Jan. 1998, p. 115, vol. 80.
- Sur, Denise K., et al., "Treatment of Allergic Rhinitis," *American Family Physician*, Jun. 15, 2010, pp. 1440-1446, vol. 81, No. 12, American Academy of Family Physicians.
- USP Monographs: Flunisolide Nasal Solution, 2013, 2 pages, USPC.
- Lieberman, Phil, "Treatment Update: Nonallergic Rhinitis," *Allergy and Asthma Proceedings*, Jul.-Aug. 2001, pp. 199-202, vol. 22, No. 4.
- Van Cauwenberge, P., et al., "Consensus statement on the treatment of allergic rhinitis," *Allergy*, 2000, pp. 116-134, vol. 55, Munksgaard, United Kingdom.
- "Nasal Polyp," Wikipedia entry, http://en.wikipedia.org/wiki/Nasal_polyp, downloaded from Internet on Apr. 3, 2013, 4 pages.
- Johansson, Gunnar, et al., "Comparison of salmeterol/fluticasone propionate combination with budesonide in patients with mild-to-moderate asthma," http://www.medscape.com/viewarticle/406237_print, [Clin Drug Invest, vol. 21, No. 9, 2001, pp. 633-642], Adis International Limited.
- Johnson, Malcom, "Development of fluticasone propionate and comparison with other inhaled corticosteroids," *J Allergy Clin Immunol*, Apr. 1998, vol. 101, No. 4, Part 2, pp. S434-S439, Mosby, Inc.
- Juniper, E. F., et al., "Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis," *Journal of Allergy and Clinical Immunology*, Mar. 1989, vol. 83, No. 3, cover and publication pages, pp. 627-633, American Academy of Allergy and Immunology, C.V. Mosby Co.
- Knobil, K., et al., "Adding salmeterol is more effective than increasing the dose of fluticasone for patients with asthma who are symptomatic on low dose fluticasone," *European Respiratory Journal*, vol. 12, Suppl. 29, Dec. 1998, pp. 19s-20s plus 1 cover page, Ref. No. P160.
- Kooreman, H. J., et al., "The synthesis of 17-esters of corticosteroids protection of 11 β -hydroxyl of the trimethylsilyl group," *Synthetic Communications*, vol. 1, No. 2, pp. 81-87, 1971, Marcel Dekker, Inc.
- Laforce, Craig F., et al., "Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents," *The Journal of Family Practice*, 1994, vol. 38, No. 2 (Feb), pp. 145-152, Appleton & Lange.
- Lane, S. J., et al., "Evaluation of a new capillary electrochromatography/mass spectrometry interface using short columns and high field strengths for rapid and efficient analyses," *Rapid Communications in Mass Spectrometry*, vol. 10, 1996, pp. 733-736, John Wiley & Sons, Ltd.
- Li, Zheng, et al., "Synthesis of aryl 5-(2-chlorophenyl)-2-furoates under phase transfer catalysis," *Synthetic Communications*, vol. 32, No. 20, pp. 3081-3086, 2002, Marcel Dekker, Inc.
- Linder, A., "Symptom scores as measures of the severity of rhinitis," *Clinical Allergy*, 1988, vol. 18, pp. 29-37.
- Lumry, William R., "A review of the preclinical and clinical data of newer intranasal steroids in the treatment of allergic rhinitis," *J Allergy Clin Immunol*, Oct. 1999, vol. 104, No. 4, Part 1, pp. S150-S158 plus correction p. 394 dated Feb. 2000, Mosby, Inc.
- Lyseng-Williamson, Katherine A., et al., "Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease," *Am J Respir Med*, vol. 1, No. 4, 2002, pp. 273-282, Adis International Limited.
- Malhotra Exhibit A, Aug. 2011, 7 pages.
- Malhotra Exhibit B, Aug. 2011, 6 pages.
- Maus Exhibit B, Aug. 2011, 2 pages.
- May, Percy, et al., "May's Chemistry of Synthetic Drugs," Fifth Edition, 1964, pp. 12-17 plus cover and publishing pages, Longmans.
- Mealy, N. E., et al., "Ciclesonide: treatment of allergic rhinitis antiallergy/antiasthmatic," XP009041019, *Drugs of the Future*, vol. 26, No. 11, Nov. 2001, pp. 1033-1039, Prous Science.
- Meltzer, Eli O., "Allergic rhinitis: Managing the pediatric spectrum," *Allergy and Asthma Proceedings*, Jan.-Feb. 2006, vol. 27, No. 1, pp. 2-8, Oceanside Publications, Inc., U.S.A.
- Meltzer, Eli O., et al., "Onset of therapeutic effect of fluticasone

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.